|
Index | - | P/E | - | EPS (ttm) | -0.99 | Insider Own | 0.10% | Shs Outstand | 24.11M | Perf Week | -6.42% |
Market Cap | 18.50M | Forward P/E | - | EPS next Y | - | Insider Trans | 122.85% | Shs Float | 14.50M | Perf Month | -25.55% |
Income | -4.50M | PEG | - | EPS next Q | - | Inst Own | 12.10% | Short Float | 0.98% | Perf Quarter | -7.27% |
Sales | 0.60M | P/S | 30.84 | EPS this Y | -26.10% | Inst Trans | 75.18% | Short Ratio | 0.04 | Perf Half Y | 61.70% |
Book/sh | 0.35 | P/B | 2.91 | EPS next Y | - | ROA | -218.30% | Target Price | - | Perf Year | -63.04% |
Cash/sh | 0.18 | P/C | 5.78 | EPS next 5Y | - | ROE | -418.50% | 52W Range | 0.54 - 3.50 | Perf YTD | 33.49% |
Dividend | - | P/FCF | - | EPS past 5Y | 39.60% | ROI | -417.10% | 52W High | -70.86% | Beta | -0.16 |
Dividend % | - | Quick Ratio | 10.40 | Sales past 5Y | 21.20% | Gross Margin | 26.10% | 52W Low | 90.62% | ATR | 0.17 |
Employees | 10 | Current Ratio | 10.70 | Sales Q/Q | 100.00% | Oper. Margin | - | RSI (14) | 39.56 | Volatility | 16.39% 13.43% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 46.40% | Profit Margin | - | Rel Volume | 0.43 | Prev Close | 0.96 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 3.73M | Price | 1.02 |
Recom | 2.00 | SMA20 | -21.50% | SMA50 | -10.65% | SMA200 | -15.22% | Volume | 1,616,439 | Change | 6.57% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite